In the dalcetrapib on cardiovascular mortality and morbidity in clinically stable patients with a recent acute coronary syndrome (dal-OUTCOMES) trial, no significant association was observed between higher HDL-C levels (40% increase) and the risk of MACEs (a composite of death from coronary heart disease, non-fatal MI, ischaemic stroke, unstable angina, or cardiac arrest with resuscitation); treatment with 600 mg of dalcetrapib had a negligible effect on LDL-C and apoB levels (Table 2, [37]). Here, APOB is linked to ischemic stroke.